Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Astria Therapeutics ( NASDAQ: ATXS) is a Boston-based pre-commercial biotech developing two late-stage candidates (Navenibart and STAR-0310). The company was initially known as Catabasis ...

Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant ...

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

CSL shares have faced several headwinds over the past year. Here's what we can expect next from the biotech business.

Five acquisitions in 2025—including Cargo and Allakos—have put Concentra Biosciences in the spotlight. Learn what’s behind ...